Table 1. Blood levels of various NNRTIs.

Drug (in vitro EC 50)	Author	Daily Dose	Limitations	Measured after intake	Measured samples	C mean (ng/ml)	C max (ng/ml)	Number of blood levels > EC50	Ratio EC50 / C mean
EFV	Manosuthi 2005 [19]	1x600mg	concurrent Rifampicin	12h	42	3020	12210	1 (2.4%)	3.3
(31.5μmol/l =	“	1x800mg	concurrent Rifampicin	12h	42	3390	21310	6 (14.3%)	2.9
9944ng/ml)	Marzolini 2001 [20]	1x600mg		14h	171	2188	15230	6 (3.5%)	4.5
	Gutierrez 2005 [21]	1x600mg		12h	58	4120	12590	3 (5.2%)	2.4
NVP	Ratanasuwan 2012 [22]	2x200mg		Post-dose	108	6671	~25000	0	9.6
(239μmol/l =	Nafrialdi 2012 [23]	2x200mg			24	7950	~15000	0	8.0
63786ng/ml)	Wang 2011 [17]	2x200mg	CR group	2h	87	6850	~15000	0	9.3
	“	2x200mg	CR group	12h	34	5180			12.3
ETR	DeJesus 2010 [24]	1x400mg		4h	20	801	1410	0	48.4
(89.0μmol/l =	Kakuda 2009 [25]	2x800mg	early formulation	3h	15	935			41.5
38740ng/ml)	Gruzdev 2003 [26]	2x900mg	early formulation	3h	12	418			92.7
LSV	Vourvahis 2012 [27]	1x2400mg	healthy volunteers	4h	48	1727	~3000	0	97.6
(543μmol/l =	Vourvahis 2010 [28]	1x750mg	healthy volunteers	4h	14	1524			111
168523ng/ml)	Vourvahis 2012 [29]	2x1000mg	healthy volunteers	4h	16	1328			127
DLV (171μmol/l	Justesen 2004 [30]	2x1000mg	healthy volunteers	1h	3	14890	24840	0	5.2
= 78072ng/ml)	Cheng 1997 [31]	3x400mg		1h	8	12144			6.4
RPV (24.4μmol/l	Goebel 2006 [32]	1x150mg		4h	9	922			9.7
= 8941ng/ml)	Ford 2013 [33]	1x25mg	healthy volunteers	4h	16	148			60.4

Several studies about blood concentrations of NNRTIs in patients are compared to the in vitro EC50 of cytotoxicity against cancer cells. (C mean: mean of all measured blood concentrations in a cohort; C max: highest blood concentration measured in one patient in a cohort)